Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 7, 2009, Pages 861-866

  Yoon, Young Joon ^a   Han, Kwang Hyub ^a   Kim, Do Young ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Early detection; Hepatitis B virus; Hepatocellular carcinoma; PIVKA II

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LUMINESCENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; PROTHROMBIN; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70350686384     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520902903034     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;/94:/153-6. (Pubitemid 32911406)
2. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;/27:/273-8.
3. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;/26:/34S-8S.
4. Zaman SN, Johnson PJ, Williams R. Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. Cancer 1990;/65:/1607-10.
5. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;/25S:/3-8.
6. Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis 2007;/11:/817-37.
7. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;/362:/1907-17.
8. Wong GL,Wong VW, Tan GM, Ip KI, Lai WK, Li YW, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008;/28:/79-87.
9. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005;/19:/91-9.
10. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;/34:/570-5.
11. Gupta S, Bent S, Kohlwes J. Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003;/139:/46-50.
12. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002;/62S:/57-63.
13. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001;/ 34:/603-5.
14. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;/310:/1427-31.
15. Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Ballucci A, et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg 1995;/ 1:/249-55.
16. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000;/95:/1036-40.
17. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993;/18:/990-7.
18. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma-carboxy prothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;/ 37:/1114-21.
19. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;/91:/561-9.
20. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer, 4th ed. Tokyo, Japan: Kanehara & Co. Ltd.; 2000.
21. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL panel of experts on HCC: clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;/35:/ 421-30.
22. Yuen MF, Lai CL. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol 2003;/14:/ 1463-7.
23. Tremolda F, Benevegnù L, Drago C, Casarin C, Cechetto A, Realdi G, et al. Early detection of hepatocellular carcinoma in patients with cirrhosis by alphafetoprotein, ultrasound and fine-needle biopsy. Hepatogastroenterology 1989;/36:/ 519-21.
24. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000;/ 95:/1535-8.
25. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, et al. Sensitivity and specificity of desgamma- carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;/101:/2038-43.
26. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;/ 226:/533-42.
27. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;/33:/1394-403.
28. Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto T, Daikoku M, et al. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003;/98:/2671-7.